Cargando…
A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma
BACKGROUND: The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-year overall survival rate is just 63% even for the pathological IA stage. Thus, in order to identify high-risk patients and facilitate clinical decision making, it is vital that we identify new progn...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
PeerJ Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465999/ https://www.ncbi.nlm.nih.gov/pubmed/34631307 http://dx.doi.org/10.7717/peerj.11911 |